Nuveen’s Protalix BioTherapeutics PLX Stock Holding History

Nuveen’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Hold	90,188	–	–	﹤0.01%	3625
2026 Q1	$196K	Hold	90,188	–	–	﹤0.01%	3098
2025 Q4	$162K	Hold	90,188	–	–	﹤0.01%	3178
2025 Q3	$200K	Hold	90,188	–	–	﹤0.01%	3149
2025 Q2	$133K	Buy	+90,188	New	+$185K	﹤0.01%	3227
2024 Q2	–	Sell	-271,795	Closed	-$342K	–	3397
2024 Q1	$342K	Hold	271,795	–	–	﹤0.01%	3074
2023 Q4	$484K	Buy	271,795 +9,714	+4%	+$15.1K	﹤0.01%	3013
2023 Q3	$435K	Hold	262,081	–	–	﹤0.01%	2890
2023 Q2	$524K	Buy	+262,081	New	+$624K	﹤0.01%	2907

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen's PLX Position: Q2 2026 in Review

Nuveen held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 90,188 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #3625.

Nuveen first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. The position peaked at $524K in Q2 2023. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Nuveen held 90,188 shares of Protalix BioTherapeutics worth $210K as of Q2 2026.
Nuveen left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3625 holding.
Nuveen first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
Nuveen's Protalix BioTherapeutics position peaked at $524K in Q2 2023.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.